Emerging treatments

Statins

Statins were previously proposed by American guidelines and supported by some experts for the prevention of vasospasm in patients with subarachnoid haemorrhage (SAH).[179] However, evidence of benefit in this population is mixed and more recent American guidelines do not recommend the routine use of statins in patients with aneurysmal SAH.[34]​[180][181][182]​ The mechanism by which statins may reduce vasospasm is uncertain, although it is believed they may potentially improve cerebral vasomotor reactivity.[179] European and UK guidelines do not make any recommendations regarding their use in SAH to prevent vasospasm or delayed cerebral ischaemia.[39][40]​ 

Endothelin-1 antagonists

Endothelin-1 antagonists have been investigated for their presumed neuroprotective effect in the treatment of SAH. However, they have not been shown to be beneficial in terms of mortality and clinical outcomes in SAH patients. [ Cochrane Clinical Answers logo ]

Magnesium sulfate

Intravenous magnesium sulfate does not improve disability, dependence, or death at 3 months after SAH.[183]

Use of this content is subject to our disclaimer